Xencor (NASDAQ:XNCR) Trading Down 6.1% - Time to Sell?

Xencor, Inc. (NASDAQ:XNCR - Get Free Report)'s stock price fell 6.1% during mid-day trading on Monday . The company traded as low as $10.60 and last traded at $10.58. 79,704 shares were traded during mid-day trading, a decline of 87% from the average session volume of 619,308 shares. The stock had previously closed at $11.26.

Analyst Ratings Changes

A number of analysts have commented on XNCR shares. Barclays cut their price target on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a research note on Thursday. StockNews.com cut Xencor from a "hold" rating to a "sell" rating in a report on Friday, March 14th. William Blair began coverage on Xencor in a research report on Monday, April 21st. They set an "outperform" rating on the stock. Wedbush reaffirmed an "outperform" rating and issued a $31.00 price objective on shares of Xencor in a research report on Wednesday, April 30th. Finally, Wells Fargo & Company decreased their target price on Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Xencor currently has a consensus rating of "Moderate Buy" and an average target price of $29.50.

Xencor Price Performance

The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average of $10.73 and a 200-day moving average of $17.63. The firm has a market capitalization of $592.70 million, a P/E ratio of -2.60 and a beta of 0.99.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.06). Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business had revenue of $32.73 million during the quarter, compared to the consensus estimate of $23.44 million. During the same period in the previous year, the firm posted ($1.11) EPS. The company's revenue was up 104.6% compared to the same quarter last year. On average, sell-side analysts predict that Xencor, Inc. will post -3.68 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Nancy Valente sold 4,616 shares of the company's stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $11.03, for a total transaction of $50,914.48. Following the completion of the sale, the executive vice president now directly owns 49,169 shares in the company, valued at approximately $542,334.07. This represents a 8.58 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 4.76% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Sterling Capital Management LLC raised its position in shares of Xencor by 732.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 1,040 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Xencor during the fourth quarter valued at approximately $34,000. CWM LLC lifted its stake in Xencor by 195.5% during the first quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company's stock worth $36,000 after purchasing an additional 2,231 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Xencor by 31.0% in the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 508 shares in the last quarter. Finally, KBC Group NV increased its stake in shares of Xencor by 26.0% in the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company's stock valued at $90,000 after purchasing an additional 813 shares during the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.